TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05055427
Drug: Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)
Normalized name: Gan Cao Root
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days. In additional, patients also receive the Standard of Care (SOC) for the treatment of COVID-19 based on the Vietnam Ministry of Health guideline.~Ingredients per formula (tang): 12 grams of honey-fried Radix Glycyrrhizae, 6 grams of Rhizoma Zingiberis (stir-baked), 6 grams of Panax Ginseng. The decoction of concentrated extract is packed into aluminum foil vacuum bag, 90ml per bag, 1 formula (tang) is equivalent to 2 bags. Patients use the decoction directly from the bag.~Daily dose: 1 bag per time, 2 times per day
Study: NCT06192797
Drug: Lenvatinib plus pucotenlimab
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lenvatinib (8mg, qd) plus pucotenlimab (200mg, q3w)
Study: NCT05175001
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Only ropivacaine in ultrasound-guided thoracic paravertebral nerve block
Study: NCT05973656
Drug: Alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol dose given orally that will result in a 0.03% blood alcohol concentration (BAC).
Study: NCT05545527
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 1 were given a single dose of ferric carboxymaltose between 14 and 17 weeks of pregnancy.
Study: NCT05545527
Drug: Iron isomaltoside
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As part of the RAPIDIRON Trial, maternal participants randomized to intervention arm 2 were given a single dose of iron isomaltoside between 14 and 17 weeks of pregnancy.
Study: NCT05545527
Drug: Ferric Sulfate
Normalized name: Ferric Sulfate
DrugBank: Ferric sulfate (DB11171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As part of the RAPIDIRON Trial, maternal participants randomized to the active comparator arm were given 200 ferrous sulfate tablets immediately after randomization (\~12 weeks of pregnancy). Participants were instructed to take two tablets a day, with each tablet containing 60mg elemental iron.
Study: NCT05213221
Drug: Envafolimab
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg, subcutaneous injection, q3w
Study: NCT05213221
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8mg,QD (body weight \<60kg); 12mg, QD (body weight ≥ 60kg)
Study: NCT00003455
Drug: antineoplaston A10
Normalized name: Antineoplaston A10
DrugBank: Antineoplaston A10 (DB11702)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003455
Drug: antineoplaston AS2-1
Normalized name: ANTINEOPLASTON AS2-1 COMPONENT PHENYLACETIC ACID
DrugBank: Phenylacetic acid (DB09269)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04432662
Drug: Darbepoetin Alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of Darbepoetin Alpha (10 mcg/kg) IV x2 doses following cooling therapy.
Study: NCT04998747
Drug: AMG 701
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 701 will be administered as SC or intravenous injection.
Study: NCT04998747
Drug: AMG 701
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 701 will be administered as SC injection.
Study: NCT06640582
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine will be administered as an intravenous (IV) infusion for five days.
Study: NCT06640582
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
Study: NCT06640582
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) infusion
Study: NCT01800240
Drug: Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05870111
Drug: Citicoline (cytidine diphosphate-choline)
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000mg/day citicoline, administered orally, for 4 weeks
Study: NCT05059626
Drug: Bazedoxifene 20/Estrogens,Con 0.45Mg Tb
Normalized name: BAZEDOXIFENE 20/ESTROGENS,CON 0.45MG TB
DrugBank: Bazedoxifene (DB06401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duavee is a selective estrogen receptor modulator.
Study: NCT05526157
Drug: Finerenone (Kerendia, BAY 948862)
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Retrospective analysis using secondary data collection from various sources
Study: NCT05526157
Drug: Sodium-glucose cotransporter 2 inhibitors (SGLT2i)
Normalized name: glucose / sodium chloride
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Retrospective analysis using secondary data collection from various sources
Study: NCT05526157
Drug: Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
Normalized name: Glucagon-like peptide II (2-glycine) (human)
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Retrospective analysis using secondary data collection from various sources
Study: NCT05526157
Drug: Steroidal mineral corticoid receptor antagonists (sMRA)
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrospective analysis using secondary data collection from various sources
Study: NCT04725188
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg\^m2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity. Docetaxel will serve as part of an experimental treatment in Arm 1, and as an active comparator in Arm 3.
Study: NCT04390945
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab combined with concurrent radiotherapy and chemotherapy
Study: NCT06148948
Drug: BI 1584862
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1584862
Study: NCT06100276
Drug: AMT-162
Normalized name: AMT-162
DrugBank: AMT-162 (DB17922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMT-162, the investigational product (IP), is a nonreplicating, rep/cap-deleted, self-complementary Recombinant adeno-associated virus (rAAV) vector based on adeno-associated virus (AAV) serotype rh10 and contains complementary deoxyribonucleic acid (cDNA) encoding an artificial miRNA targeting the SOD1 gene.
Study: NCT06402136
Drug: 83-0060
Normalized name: methylsulfonylmethane 83 MG
DrugBank: Dimethyl sulfone (DB14090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral MPro inhibitor
Study: NCT06636812
Drug: Losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose losartan (25mg or 50 mg, weight-adjusted), encapsulated identically to placebo
Study: NCT00002011
Drug: Methoxsalen
Normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05749445
Drug: Nirmatrelvir-Ritonavir
Normalized name: nirmatrelvir-ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nirmatrelvir-Ritonavir
Study: NCT04918771
Drug: Raphamin
Normalized name: Allantoin 0.007 g in 0.7 g TOPICAL POWDER [RAPHAGEN POWDE R]
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration - not with food. Keep the tablet in the mouth until it is completely dissolved.~On the 1st day of treatment, 8 tablets are taken according to the following scheme: 1 tablet every 30 minutes in the first 2 hours (a total of 5 tablets in 2 hours), then during the same day, take another 1 tablet 3 times at regular intervals. On the 2nd day and then take 1 tablet 3 times a day. The duration of treatment is 5 days.
Study: NCT04782180
Drug: Descovy 200Mg 25Mg Tablet
Normalized name: Descovy
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: daily Descovy tab by mouth
Study: NCT04551053
Drug: parsaclisib
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: parsaclisib will be administered QD orally
Study: NCT04551053
Drug: ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ruxolitinib will be administered BID orally
Study: NCT06026332
Drug: ADSTILADRIN
Normalized name: Adstiladrin
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-interventional
Study: NCT05278715
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose of carboplatin is adjusted for age (over 1 year old, full dose, 220 mg/m\^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent).
Study: NCT05278715
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose of vincristine is adjusted for age (over 1 year old, full dose, 1.5 mg/m\^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent). Maximum dose is 2 mg.
Study: NCT05278715
Drug: Recombinant human endostatin
Normalized name: Recombinant human endostatin
DrugBank: Endostatin (DB06423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks.
Study: NCT00002256
Drug: Zalcitabine
Normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05059522
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral
Study: NCT05059522
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT05059522
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV (intravenous) infusion
Study: NCT05059522
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT05059522
Drug: Utomilumab
Normalized name: Utomilumab
DrugBank: Utomilumab (DB15113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06678581
Drug: SAP-001
Normalized name: HURA CREPITANS SAP
DrugBank: AP-001 (DB18511)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid Oral Tablet
Study: NCT06691542
Drug: platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: platelet-rich plasma, metformin and cryotherapy in treatment of non-genital warts
Study: NCT06691542
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: platelet-rich plasma, metformin and cryotherapy in treatment of non-genital warts
Study: NCT06694129
Drug: Entrectinib
Normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in each cohort were treated with Entrectinib.
Study: NCT06688253
Drug: IV efgartigimod
Normalized name: Efgartigimod alfa
DrugBank: Efgartigimod alfa (DB15270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV efgartigimod
Study: NCT06686121
Drug: Nitrate Rich Beetroot Juice
Normalized name: tamarind juice
DrugBank: Beet (DB10640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will drink one shot of nitrate rich beet-root juice twice daily for six months.
Study: NCT06686121
Drug: Placebo Beetroot Juice Without Nitrate
DrugBank: Beet (DB10640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will drink one shot of placebo beetroot without nitrate juice twice daily for six months.
Study: NCT06686472
Drug: TL-925
Normalized name: Thallous chloride Tl 201
DrugBank: Thallous chloride Tl-201 (DB16624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TL-925 is an eye drop.
Study: NCT04984993
Drug: Tadalafil 5mg (Male)
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets
Study: NCT04984993
Drug: Tadalafil 5mg (Female)
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets
Study: NCT06687187
Drug: Neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: two groups (Group I, n= 41) and (Group II, n= 43) received varying doses of neostigmine (1 mg and 2 mg respectively
Study: NCT06690541
Drug: Lorlatinib 100 mg
Normalized name: lorlatinib 100 MG
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients received continuous daily PO dosing of lorlatinib 100mg QD from the date of first dosing (per the current protocol) or until one of the following criteria were met (whichever occurred first): disease progression; initiation of a new anticancer therapy; unacceptable toxicities; global deterioration of health-related symptoms; pregnancy; withdrawal of consent; loss to follow-up; death; investigator decision dictated by protocol non-compliance; or study termination.
Study: NCT06694740
Drug: Interferon Gamma 1-b
Normalized name: Interferon gamma 1-b
DrugBank: Interferon gamma-1b (DB00033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: interferon gamma-1b 2 X 106 IU, injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections)
Study: NCT05856630
Drug: Goserelin Acetate Sustained-Release Microspheres for Injection
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10.8mg, Single dose, subcutaneously（SC）
Study: NCT06691633
Drug: Preoperative Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient receives a one-time preoperative dose of 10 mg of methadone
Study: NCT06691633
Drug: Preoperative Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patient receives a one-time preoperative dose of 10 mg of oral oxycodone
Study: NCT06688045
Drug: Nemtabrutinib
Normalized name: Nemtabrutinib
DrugBank: Nemtabrutinib (DB18866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06688045
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration
Study: NCT01442571
Drug: Saline Injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05918146
Drug: Dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose injection plus physical therapy
Study: NCT05301972
Drug: BET Inhibitor
Normalized name: BET INHIBITOR TEN-010
DrugBank: RO-6870810 (DB15151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromodomain and Extra-Terminal Inhibitor
Study: NCT05712538
Drug: ARCT-032
Normalized name: ARCT-810
DrugBank: ARCT-810 (DB17683)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARCT-032 is messenger RNA (mRNA) coding for cystic fibrosis transmembrane conductance regulator (CFTR) protein, formulated in a lipid nanoparticle (LNP).
Study: NCT06694350
Drug: Pembrolizumab+Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pembrolizumab 200mg ivgtt once +Flutamide 250mg，Q8h
Study: NCT05691829
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200mg solution administered intravenously every 3 weeks for 6 cycles followed by maintenance therapy until progression of disease or unacceptable toxicity (standard of care). Administered alongside chemotherapy.
Study: NCT05592743
Drug: Vorasidenib
Normalized name: Vorasidenib
DrugBank: Vorasidenib (DB17097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral therapy
Study: NCT04867798
Drug: Lamivudine-Tenofovir 300 Mg-300 Mg Oral Tablet
Normalized name: lamivudine-tenofovir 300 mg-300 mg oral tablet
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PrEP eligible participants will be asked to follow up monthly for 12 months. PrEP will be prescribed for once-daily use and discontinued if HIV tests are positive. At quarterly visits, participants will receive Integrated Next Steps Counseling (iNSC) for PrEP adherence with point-of-care drug level feedback. Participants will receive iNSC Support Level 1 to address PrEP adherence and sexual health needs. Those with urine tenofovir levels \<1500 ng/mL will receive iNSC Support Level 2, in which participant responses to two 7-item questionnaires on PrEP adherence and sexual health will guide problem solving on improved dosing. Medication refills will consist of 3-month supplies.
Study: NCT05584137
Drug: HLX26
Normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
Study: NCT05584137
Drug: HLX10
Normalized name: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.-chain, dimer
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humanized Anti-Programmed Death-1 Monoclonal Antibody
Study: NCT06132204
Drug: HRS-7535 Tablets
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-7535 Tablets
Study: NCT05654181
Drug: PF-07328948
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: investigational drug administered orally
Study: NCT06177431
Drug: Monepantel
Normalized name: Monepantel
DrugBank: Monepantel (DB18755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals
Study: NCT05543174
Drug: TAK-625
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-625 200 mcg or 400 mcg per kilogram, orally, once daily
Study: NCT05535855
Drug: CD19 Directed CAR T Cell
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The UCD19 CAR T cells are developed through transfection of autologous peripheral blood mononuclear cells with a lentivirus carrying the DNA that encodes a short chain fragment variable region (scFv) derived from an anti-CD19 monoclonal antibody, among other elements.
Study: NCT04695925
Drug: Osimertinib 80 MG [Tagrisso]
Normalized name: osimertinib 80 MG [Tagrisso]
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: osimertinib 80 mg po qd until disease progression
Study: NCT04695925
Drug: Pemetrexed 500 MG Injection
Normalized name: pemetrexed 500 MG Injection
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pemetrexed 500 mg/m2 intravenously every 3 weeks until disease progression
Study: NCT04695925
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin area under curve 5 intravenously every 3 weeks for four cycles
Study: NCT04995133
Drug: Colistin
Normalized name: Colistin
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous administration
Study: NCT05833139
Drug: BI 1810631
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1810631
Study: NCT05833139
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole
Study: NCT05338320
Drug: Intrathecal morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: General anesthesia and intrathecal morphine
Study: NCT06633328
Drug: CD7 CAR-T cells injection
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD7 CAR T cells treat patients with severe aplastic anemia
Study: NCT06160778
Drug: Ketorolac Tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ketorolac given at 0.5 mg/kg of body weight up to a maximum of 30 mg in a single dose.
Study: NCT06160778
Drug: Morphine Sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous morphine given at 0.1 mg/kg of body weight up to a maximum of 5 mg in a single dose.
Study: NCT03841474
Drug: Psychiatric treatment with sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychiatric treatment with sertraline (range from 50 mg/day to 200mg/day according to clinical appearance) of newly recognized depression in patients after PCI
Study: NCT03841474
Drug: Psychiatric treatment with escitalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychiatric treatment with escitalopram (range from 10 mg/day to 20 mg/day according to clinical appearance) of newly recognized depression in patients after PCI
Study: NCT04952519
Drug: Amantadine
Normalized name: Amantadine
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are treated with high doses of amantadine.
Study: NCT04874597
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab treatment will be administered in accordance with the product characteristics approved in Turkey.
Study: NCT06370663
Drug: HAIC (GEMOX)
Normalized name: Hemox A
DrugBank: Aluminum chloride (DB11081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic Arterial Infusion Chemotherapy (GEMOX)
Study: NCT05642845
Drug: Atorvastatin film-coated tablet 40 mg
Normalized name: atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of atorvastatin.
Study: NCT06049160
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will be assigned for giving misoprostol rectally either preoperative or postoperative